The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Medtronic MDT has started the year 2025 on a positive note, with the stock climbing nearly 7% so far in January. This surge in market optimism follows the CMS' recent move to initiate a national ...

The global cardiovascular devices market, valued at US$ 72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3%, reaching US$ ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, Martha said Monday at the J.P. Morgan Healthcare Conference.

National coverage analysis is the first-of-its kind for a minimally invasive, interventional <a target=_blank href ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal ...